Orion invites analysts and media to Q3 news conference on Tuesday 23 October 2012


ORION CORPORATION STOCK EXCHANGE RELEASE 9 OCTOBER 2012 at 9.55 AM EEST

Orion will publish its Interim Report January-September 2012 on Tuesday, 23
October 2012 approximatelyat 12:00 Finnish time (EEST). The release and related
presentation material in Finnish and in English will be available on the Group's
homepage at www.orion.fi/en/investors promptly after the publishing.

News conference for analysts and mediaon Tuesday 23 October 2012 at 13:30 EEST

A news conference for analysts and mediawill be held on Tuesday 23 October 2012
at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President
and CEO Timo Lappalainen will give a brief presentation in English on the
financial review.

Live webcast and conference call

The event can be followed live as a webcast accessible at
http://qsb.webcast.fi/o/orion/orion_2012_1023_q3/

Questions can be asked also through conference call lines after the result
presentation.

The conference call ID is 914 113 and the phone numbers to participate the
conference are:
when calling from the United States +1 334 323 6203
when calling from other countries +44 (0)20 7162 0125

News conference recordings

A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent period

The silent period preceding the publication is ongoing and continues until the
disclosure.

Orion Corporation

 Timo Lappalainen  Jari Karlson
 President and CEO CFO


Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.

Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



[HUG#1647551]